Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine dose-escalation study in chronic spontaneous urticaria
2014-000181-21Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bilastine in chronic idiopathic urticaria (CIU), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Complete responder rate across dose-escalation timepoints. Started Apr 2014; status: completed.
02
Drugs
bilastine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2014-000181-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000181-21.